These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

633 related items for PubMed ID: 32980422

  • 21. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
    Csanyi-Bastien M, Lanic MD, Beaussire L, Ferric S, François A, Meseure D, Jardin F, Wassef M, Ruminy P, Laé M.
    Am J Surg Pathol; 2021 Nov 01; 45(11):1487-1498. PubMed ID: 33899788
    [Abstract] [Full Text] [Related]

  • 22. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
    Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, Park KJ, Soslow RA, Oliva E, Iafrate AJ, Benayed R, Ladanyi M, Antonescu CR.
    Am J Surg Pathol; 2018 Jun 01; 42(6):791-798. PubMed ID: 29553955
    [Abstract] [Full Text] [Related]

  • 25. Clinicopathologic Features and Cytologic Correlation of ALK-Rearranged Papillary Thyroid Carcinoma: A Series of Eight Cases.
    Shih KP, Lee YC, Tsai JJ, Lin SH, Liu CY, Li WS, Li CF, Hang JF.
    Endocr Pathol; 2024 Jun 01; 35(2):134-146. PubMed ID: 38642308
    [Abstract] [Full Text] [Related]

  • 26. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, Audigier-Valette C, Sabourin JC, Decroisette C, Sakhri L, Brambilla E, McLeer-Florin A.
    Lung Cancer; 2014 Feb 01; 83(2):168-73. PubMed ID: 24380695
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS, Kim Y, Jeon S, Kim SH, Kim TJ, Lee S, Kim MH, Lim DJ, Lee YS, Jung CK.
    Diagn Pathol; 2016 Feb 09; 11():21. PubMed ID: 26857243
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Ginestet F, Lambros L, Le Flahec G, Marcorelles P, Uguen A.
    Clin Lung Cancer; 2018 Sep 09; 19(5):e647-e653. PubMed ID: 29801706
    [Abstract] [Full Text] [Related]

  • 31. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.
    Sholl LM, Sun H, Butaney M, Zhang C, Lee C, Jänne PA, Rodig SJ.
    Am J Surg Pathol; 2013 Sep 09; 37(9):1441-9. PubMed ID: 23887156
    [Abstract] [Full Text] [Related]

  • 32. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
    Clavé S, Rodon N, Pijuan L, Díaz O, Lorenzo M, Rocha P, Taus Á, Blanco R, Bosch-Barrera J, Reguart N, de la Torre N, Oliveras G, Espinet B, Bellosillo B, Puig X, Arriola E, Salido M.
    Clin Lung Cancer; 2019 Jul 09; 20(4):e421-e429. PubMed ID: 30898567
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
    Chu YH, Wirth LJ, Farahani AA, Nosé V, Faquin WC, Dias-Santagata D, Sadow PM.
    Mod Pathol; 2020 Dec 09; 33(12):2458-2472. PubMed ID: 32737449
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Molecular and Cytogenetic Features of NTRK Fusions Enriched in BRAF and RET Double-Negative Papillary Thyroid Cancer.
    Wu S, Liu Y, Li K, Liang Z, Zeng X.
    J Mol Diagn; 2023 Aug 09; 25(8):569-582. PubMed ID: 37236546
    [Abstract] [Full Text] [Related]

  • 39. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B, Godbert Y, Perot G, Al Ghuzlan A, Bardet S, Belleannée G, Crinière L, Do Cao C, Fouilloux G, Guyetant S, Kelly A, Leboulleux S, Buffet C, Leteurtre E, Michels JJ, Tissier F, Toubert ME, Wassef M, Pinard C, Hostein I, Soubeyran I.
    Thyroid; 2017 May 09; 27(5):682-692. PubMed ID: 28351340
    [Abstract] [Full Text] [Related]

  • 40. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
    Nikitski AV, Rominski SL, Condello V, Kaya C, Wankhede M, Panebianco F, Yang H, Altschuler DL, Nikiforov YE.
    Thyroid; 2019 Oct 09; 29(10):1425-1437. PubMed ID: 31298630
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.